Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07163702
PHASE2

Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke

Sponsor: Dongzhimen Hospital, Beijing

View on ClinicalTrials.gov

Summary

This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.

Official title: Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke (EXACT): a Multi-center, Randomized, Double-blinded, Dose-exploration Ⅱa Trial

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2025-10-01

Completion Date

2026-09-30

Last Updated

2025-09-09

Healthy Volunteers

No

Interventions

DRUG

High-dose Xinglou Chengqi granules

Patients will receive orally high-dose Xinglou Chengqi granules, combined with guidelines-based standard care.

DRUG

Low-dose Xinglou Chengqi granules and placebo

Patients will receive orally low-dose Xinglou Chengqi granules, combined with guidelines-based standard care.

Locations (1)

Dongzhimen Hospital, Beijing University of Chinese Medicine

Richmond, British Columbia, Canada